STOCK TITAN

Director at OPKO (NASDAQ: OPK) receives grant of 60,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

OPKO HEALTH, INC. director Richard C. Pfenniger Jr. received a grant of stock options representing 60,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. After this award, he holds 60,000 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider PFENNIGER RICHARD C JR
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 60,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 60,000 shares (Direct, null)
Footnotes (1)
Options granted 60,000 options Stock Option (Right to Buy) grant to director
Exercise price $1.42 per share Conversion or exercise price for options
Shares underlying options 60,000 shares Underlying OPKO common stock
Post-transaction derivative holdings 60,000 options Total derivative securities following transaction
Exercise start date June 18, 2027 Option exercise date
Expiration date June 17, 2036 Option expiration
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative securities financial
"derivativeTransactionCount and derivative type transaction"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
exercise price financial
"conversion_or_exercise_price: 1.4200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-17T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PFENNIGER RICHARD C JR

(Last)(First)(Middle)
OPKO HEALTH, INC.
4400 BISCAYNE BLVD.

(Street)
MIAMI FLORIDA 33137

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.4206/18/2026A60,00006/18/202706/17/2036Common Stock60,000$060,000D
Explanation of Responses:
Steven D. Rubin, Attorney-in-Fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did OPKO (OPK) director Richard C. Pfenniger Jr. report on this Form 4?

He reported receiving a grant of stock options for 60,000 OPKO shares. These derivative securities give him the right to buy common stock at a fixed price and are recorded as a compensation-related acquisition.

How many OPKO stock options were granted to Richard C. Pfenniger Jr.?

He was granted stock options covering 60,000 shares of OPKO common stock. This entire amount is reported as directly owned derivative securities following the transaction on the Form 4.

What is the exercise price of the OPKO options granted to Richard C. Pfenniger Jr.?

The options have an exercise price of $1.42 per share. This means he can purchase OPKO common stock at $1.42 for each optioned share once the options are exercisable and before they expire.

When do Richard C. Pfenniger Jr.’s OPKO stock options become exercisable and when do they expire?

The options become exercisable on June 18, 2027 and expire on June 17, 2036. This gives a multi-year window in which he can choose to exercise the right to buy shares at the fixed price.

Is this OPKO Form 4 a market purchase or sale of shares?

No, it reports a grant of derivative securities rather than a market trade. The Form 4 describes stock option awards, not open-market buying or selling of OPKO common stock by the director.